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Abstract
The recent roll-out of rapid diagnostic tests (RDTs) for malaria has highlighted the decreasing proportion of malaria-attributable illness in
endemic areas. Unfortunately, once malaria is excluded, there are few accessible diagnostic tools to guide the management of severe febrile
illnesses in low resource settings. This review summarizes the current state of RDT development for several key infections, including
dengue fever, enteric fever, leptospirosis, brucellosis, visceral leishmaniasis and human African trypanosomiasis, and highlights many
remaining gaps. Most RDTs for non-malarial tropical infections currently rely on the detection of host antibodies against a single infectious
agent. The sensitivity and speciﬁcity of host-antibody detection tests are both inherently limited. Moreover, prolonged antibody responses
to many infections preclude the use of most serological RDTs for monitoring response to treatment and/or for diagnosing relapse.
Considering these limitations, there is a pressing need for sensitive pathogen-detection-based RDTs, as have been successfully developed
for malaria and dengue. Ultimately, integration of RDTs into a validated syndromic approach to tropical fevers is urgently needed. Related
research priorities are to deﬁne the evolving epidemiology of fever in the tropics, and to determine how combinations of RDTs could be
best used to improve the management of severe and treatable infections requiring speciﬁc therapy.
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Introduction
The recent roll-out of rapid diagnostic tests (RDTs) for malaria
has highlighted the decreasing proportion of malaria-attribut-
able illness in endemic areas [1–4], and that the proportion of
patients evaluated for fever suffering from a condition other
than malaria is likely to continue increasing with time [5–8].
Unfortunately, once malaria is excluded, there are few
accessible diagnostic tools to guide the management of severe
febrile illnesses in low resource settings. Making matters worse,
very little epidemiological data underpins clinicians’ assessment
of prior probability in vast areas of Africa and Asia. How-
ever, wherever systematically studied, various non-malarial
infections have been found to be major causes of febrile
syndromes in tropical settings, such as relapsing fever [9],
leptospirosis [10,11], rickettsial infection [12], dengue [13] or
typhoid fever [14]. Such infections can be severe and most are
treatable with speciﬁc therapy, but often clinically indistin-
guishable without conﬁrmatory tests.
Based on the successful contribution of RDTs to malaria and
HIV diagnosis, several point-of-care assays and RDTs designed
for peripheral health facilities have been or are being developed
for other tropical infections to improve patient care and
epidemiological surveillance. The purpose of this article is to
review currently available RDTs for the individual case-manage-
ment of non-malarial tropical infections presenting with acute
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or persistent fever. Priority has been given to RDTs
detecting potentially severe illnesses of proven or suspected
epidemiological importance, requiring speciﬁc management, for
which ‘immediate’ diagnosiswould bemost useful. In this review,
we will not focus on RDTs developed for febrile illnesses with
predominantly focal symptoms, such as respiratory or diarrho-
eal infections.
For this review, RDTs are deﬁned as any test yielding results
within minutes and that can be performed in health centres with
little infrastructure or trained personnel, preferably without
electricity. These are nearly all immunoassays, in various formats.
New generations of such tests are increasingly single-step lateral
ﬂow assays (immunochromatographic tests in the form of a
dipstick or cassette), which offer technical and operational
advantages over older formats such as latex agglutination kits,
ﬂocculation assays and vertical ﬂow-through assays [15–17].
Diseases
The epidemiological, clinical and reference diagnostic features
of the diseases presented below are summarized in Table 1.
Dengue and chikungunya
The retrospective nature of classical serological tests to
conﬁrm dengue does not help clinicians to manage acutely ill
patients (Table 1). The new combined RDTs that detect both
IgM/IgG and the NS1 antigen provide immediate results and
are able to diagnose dengue at different points in time after
initiation of symptoms (Table 2).
The NS1 antigen is highly speciﬁc and detectable in serum
from days 1 to 9 after fever onset [18,19]; its sensitivity depends
on the type of test used and the time since onset of symptoms (it
declines in parallel with viraemia), and is higher in primary than
secondary dengue [20–22]. Tests detecting speciﬁc IgM anti-
bodies are generally sensitive for diagnosing dengue, but not in
the ﬁrst days of fever. In a study among travellers in Israel, IgM
became detectable between days 4 and 8 of fever [23]. Tests that
combine detection of NS1 and IgM can therefore diagnose
dengue throughout the febrile illness. The sensitivity of
combined NS1/antibody tests was 76–93% in six recent studies
conducted in endemic areas (Table 2). Sensitivity was even
higher (96%) among travellers, who are more likely to present
with primary dengue [24]. Whereas speciﬁcity of the NS1 band
is very high (>95% in most studies), speciﬁcity of the IgM band is
sometimes lower in endemic areas due to cross-reactivity with
other pathogens, mainly Chikungunya virus [25]. Only two
combined NS1/antibody RDTs that have been evaluated in
endemic areas are commercially available: RDT from Panbio
(Inverness Medical Innovations, Brisbane, Australia), presently
available in two separate cassettes (Panbio Dengue Early
RapidTM, detecting NS1, and Panbio Dengue Duo CassetteTM,
detecting IgM/IgG), and the SD Bioline Dengue DuoTM (Standard
Diagnostics, Kionggi, Korea), detecting both NS1 and IgM/IgG in
two cassettes bonded together.
Chikungunya is an emerging alphavirus with wide geograph-
ical distribution [26]. RDTs based on IgM detection have been
recently developed with limited ﬁeld validation. Sensitivity was
poor in the ﬁrst week of illness but increased afterwards [27,28].
Enteric fever
The diagnosis of enteric fever is notoriously difﬁcult, owing to
its non-speciﬁc clinical presentation, a very low number of
circulating bacteria in blood [29], and antigenic similarity to
other members of the Enterobacteraceae [30]. The Widal test is
a simple serological assay detecting antibodies against lipo-
polysaccharide (LPS; O) and ﬂagellar (H) antigens of S. Typhi.
Introduced over 115 years ago, this test continues to be
widely used despite its unacceptably low accuracy [31–35].
Numerous RDTs based on host antibody detection have
attempted to improve diagnostic performance, with limited
success (Table 3). The IDL TUBEX TFTM (IDL Biotech AB,
Bromma, Sweden) is a semi-quantitative colorimetric test
detecting anti-0:9 IgM antibodies. Results are available within
3 min at room temperature and require minimal laboratory
supplies. The TyphidotTM platform (Reszon Diagnostics Interna-
tional Sdn. Bhd., Selangor, Malaysia) qualitatively detects anti-
bodies to the outer membrane protein (Vi; OMP) and is
commercialized in three forms: the TyphidotTM detects either
IgM or IgG antibody via an enzyme immunoblot assay and yields
qualitative results in 60 min; the Typhidot Rapid IgMTM and
Typhidot Rapid IgM IgG ComboTM are immunochromatographic
(ICT) cassettes featuring separate lines for IgG and IgM and yield
results in 15 min. Other commercialized RDTs include the RTI
LPS IgM ICTTM (Royal Tropical Institute, Amsterdam, the
Netherlands; now produced by LifeAssay Diagnostics Ltd)
detecting anti-LPS (O antigen) IgM, and the Typhoid Rapid
TestTM (SD Bioline, Kionggi, Korea) detecting total IgM/IgG
against an unspeciﬁed S. Typhi antigen. All of these RDTs detect
antibodies against antigens selected from S. Typhi isolates.
TUBEX and Typhidot are non-reactive with sera from S.
Paratyphi infections [36]. Conversely, the RTI LPS IgM ICT is
equally sensitive for infections from S.Typhi andS.Paratyphi [37].
In general, the sensitivity of serological tests is unsatisfac-
tory initially and increases with longer duration of illness. In
Indonesia, the sensitivity of Widal and the RTI LPS IgM ICT
increased from 43–48% at days 4–6 of fever to 90–100% after
more than 9 days, compared with positive blood cultures [37].
The reported speciﬁcity of RDTs is affected by imperfect
sensitivity of reference standard blood cultures, and rises from
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46–80% when clinical suspects with negative blood cultures are
used as controls, to 83–100% when controls have an
established alternative diagnosis (Table 3). In addition, numer-
ous other host factors may affect the speciﬁcity of antibody-
detection tests. Thus, the modest accuracy of available RDTs
for early enteric fever precludes their routine use, except
perhaps in the setting of a high pre-test probability, such as
during outbreaks [14].
TABLE 1. Epidemiology, clinical features and reference diagnostic tests of dengue fever, enteric fever, leptospirosis, brucellosis,
human African trypanosomiasis and visceral leishmaniasis
Disease Burden and epidemiology Clinical features Reference diagnostic testing
Dengue fever Annual global incidence estimated at
50–100 million cases. 500 000 people
with severe dengue require
hospitalization each year, esentially
children, of whom about 2.5% die.
Dengue is found in tropical and
sub-tropical climates worldwide,
mostly in urban and semi-urban areas.
About half of the world’s population
is now at risk.
Transmitted by Aedes mosquitoes
(e.g. A. aegypti).
No animal reservoir
Suspect case deﬁned by acute fever with
at least two of the following: headache,
retro-orbital pain, myalgia, arthralgia,
nausea, vomiting, swollen glands or
rash. Symptoms usually last for 2–7 days.
Severe dengue is characterized by
shock, respiratory distress, severe
bleeding or organ impairment. Warning
signs occur 3–7 days after the ﬁrst
symptoms.
Isolation of the dengue virus from
serum, plasma, leukocytes or tissues.
Demonstration of a fourfold or
greater rise in reciprocal IgG or
IgM antibody titres to one or more
dengue virus antigens in paired
serum samples,
Detection of viral genomic sequences
in tissue, serum or CSF samples
by PCR.
Enteric fever
(Salmonella
Typhi/Paratyphi)
Annual global incidence estimated at
27 million cases (22 million S. Typhi,
5 million S. Paratyphi) with 216 150
deaths [80]. Occurs worldwide in
low/middle income countries, particularly
south/southeast Asia. African burden less
clear. Under-reporting and diagnostic
difﬁculty make precise estimates difﬁcult.
Faecal-oral transmission.
No animal reservoir.
Clinical spectrum ranging from fever and
malaise to severe complications such as
intestinal perforation and encephalopathy.
Fever generally increases abruptly after
first week of illness in untreated patients.
Splenomegaly and ﬂeeting rash may occur.
Diarrhoea in less than 50% of cases.
Recovery of Salmonella
Typhi/Paratyphi from blood or bone
marrow (BM). Recovery from intestinal
tract may represent chronic carriage.
Sensitivity <100% for all specimens,
depending on many factors. Combination
of several samples (blood, BM, urine,
gastric aspirates, rose spots) increases
yield [81].
Drawing sufﬁcient volume of blood
(i.e  20–30 mL) is the most
important factor affecting the yield
of blood cultures [29,82].
Leptospirosis Zoonotic disease caused by bacteria of the
genus Leptospira.
Worldwide distribution but true disease
burden unknown. Most common in urban
slums and rural tropics. Epidemics often
seen during ﬂooding.
Main transmission to humans by exposure to
water and soil contaminated by the urine of
infected animals (e.g. rodents) [83].
Wide spectrum from asymptomatic to
fulminant disease. Fever, malaise,
headaches, severe myalgias, conjunctival
suffusion, anorexia, nausea, vomiting
followed by aseptic meningitis in up to
25% cases. Severe forms: jaundice, renal
failure and haemorrhage (Weil’s
disease) and/or respiratory distress
Culture from blood or other body
ﬂuids has low sensitivity and very
slow growth rate.
The microscopic agglutination test
(MAT) detects serogroup-speciﬁc
IgM and IgG antibodies. Paired sera
required for deﬁnitive diagnosis
(seroconversion or fourfold increase
in titres)
Conventional and real-time PCR in
blood or serum useful for early
diagnosis, despite limited sensitivity
[51,84].
Brucellosis
(B. melitensis,
B. abortus, B. suis)
Leading zoonosis in the world, with annual
global incidence of ~500 000 cases, and
prevalence  10/100 000 in some countries [85].
Transmission by contact with ﬂuids from
infected animals or derived food products.
Reservoir is domestic livestock, differs by
Brucella species.
Worldwide occurrence, highest in Mediterranean
basin, Indian subcontinent, Mexico and Central
and South America.
Extremely wide clinical spectrum. Acute
disease presents as fever  focal
symptoms (e.g. arthritis). Chronic
disease (e.g. abscess) may be more
difﬁcult to diagnose.
Treatment requires at least 6 weeks of
dual drug therapy, and relapses are
frequent.
Recovery of Brucella species in culture
of any body ﬂuid or tissue.
Blood or bone marrow have highest
yield, and may require prolonged
incubation (up to 3 weeks) if manual
culture systems are used.
Human African
trypanosomiasis (HAT)
Exclusively in Africa; due to Trypanosoma brucei
gambiense or T. b. rhodesiense
T. b. gambiense: Foci in rural areas of west and
central Africa; most prevalent in Democratic
Republic of Congo, Central African Republic
and southern Sudan;since 2009, less than 10 000
cases reported annually but proportion of
under-reported cases unknown [86].
T. b. rhodesiense: Foci in rural areas of east and
southern Africa; less than 200 cases reported
in 2009 [86].
First (early) haematolymphatic stage:
intermittent fever, headache, pruritus,
lymphadenopathy.
Second (late) meningo-encephalitic stage:
sleep disturbances and neuropsychiatric
disorders.
More severe symptoms and faster
evolution to the meningoencephalitic
stage for T. b. rhodesiense; fatal if left
untreated.
Microscopic examination of
trypanosomes in body ﬂuid (lymph,
blood or cerebrospinal ﬂuid [CSF]).
Need for concentration methods for
T. b. gambiense HAT (e.g.
microhaematocrit centrifugation
technique, mini-anion-exchange
centrifugation technique) because of
scanty parasites. Diagnosis of second
stage HAT based on presence of
trypanosomes and/or more than 5
white blood cells per lL in CSF [58].
Visceral leishmaniasis Systemic protozoan infection due to Leishmania
donovani in South Asia and East Africa or
L. infantum in Latin America and the
Mediterranean region. 200 000–400 000 cases
occur annually in 70 countries. The ﬁve most
affected countries are India, Bangladesh, Sudan,
South Sudan and Ethiopia [87]. Fatal if left
untreated.
Prolonged fever, malaise, weight loss,
epistaxis, cough, enlarged liver and
spleen, lymphadenopathies, progressive
anaemia, concomitant infections
(e.g. pneumonia).
Microscopic examination of Leishmania
amatigote forms in aspirates from
lymph node, bone marrow or spleen.
Sensitivity >90% only with spleen
aspirate examination but risk of
major bleeding ~0.1%. Sensitivity
improved by culture or PCR. Various
serological methods with high
sensitivity and speciﬁcity: ELISA, IF,
Western blot, DAT [61,88].
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The detection of S. Typhi antigens in clinical samples has
been shown to have comparable accuracy to antibody-
detection tests [38–40]. A valuable alternative use for putative
RDTs based on such assays could be the rapid identiﬁcation of
S. Typhi/Paratyphi in culture media, greatly simplifying blood
cultures in basic laboratories.
Leptospirosis
The Lepto lateral ﬂowTM has been developed by the Royal
Tropical Institute (KIT, Amsterdam, the Netherlands) [41]. It is
based on the binding of speciﬁc IgM antibodies to a whole-cell
antigen prepared from the non-pathogenic Patoc 1 strain. In the
Andaman Islands, India, its sensitivity increasedwith the duration
of illness, from 34% on days 2–3 to 63% on days 4–5 and 85% at
the endof theﬁrstweek,with high speciﬁcity (94%) [42]. It is now
commercialized as Test-itTM Leptospira (LifeAssay Diagnostics).
Most publications of the late 1990s and early 2000s evaluated
earlier formats of RDTs developed by the KIT or commercial
RDTs that are, to our knowledge, no longer available [43–48].
The persistence of anti-leptospiral IgM after infection and
frequent exposure to non-pathogenic leptospires (e.g. during
farming) are likely to explain the limited speciﬁcity of ELISA and
RDTs using whole-cell antigens, as reported by some [48–50].
Diagnostic accuracy could theoretically be improvedwith assays
using more speciﬁc antigens [51]. A novel Dual Path Plat-
formTM(DPP) assay (Chembio Diagnostics Systems, Medford,
USA) incorporates recombinant leptospiral immunoglobulin-
like proteins as antigens. In a phase 2 study conducted in Latin
America, the assay achieved sensitivity of 85% and 64% in severe
and mild leptospirosis, respectively. Like the other serological
tests, sensitivity increasedwith durationof symptoms. Speciﬁcity
was high (>93%) in various control groups butmoderate (86%) in
healthy slum residents, suggesting some background immunity
also against this antigen in highly exposed populations [52].
The detection of leptospiral antigen in the blood or urine is
a promising approach, as it may allow for earlier diagnosis (i.e.
before the appearance of speciﬁc IgM) and therefore prompter
treatment to prevent late clinical complications [53].
Brucellosis
Serological tests detecting antibodies to Brucella spp. antigens
are the most frequently used modality for acute and chronic
TABLE 2. Selected studies evaluating RDTs for dengue fevera (adapted from Blacksell et al. [89])
Author Year Assay Country
Sample timing
(days of illness) Reference comparator
Antigen or
antibody
detected
Sensitivity%
(95% CI)
Speciﬁcity%
(95% CI)
Shu et al. [90] 2009 BioRad STRIP Taiwan 1–7 (median: 2) PCR or paired ELISA NS1 77.3 (0.54–0.92) 100
Hang et al. [91] 2009 Vietnam 1–6 PCR or paired ELISA NS1 72.8 (64.1–80.3) 100 (91.6–100)
Chaiyaratana et al. [92] 2009 Thailand 1–8 NS1 Ag ELISA NS1 98.9 (96.8–100) 90.6 (85.6–95.7)
Ramirez et al. [93] 2009 Venezuela 2–6 PCR or paired ELISA NS1 67.8 (57.4–76.7) 94.4 (80.9–99.4)
Lima et al. [94] 2010 Brazil 1–6 Combinations of viral
culture, PCR, NS1
Ag ELISA
NS1 89.6 (84.7–93.2) 99.1 (96.9–99.9)
Tricou et al. [95] 2010 Vietnam 1–6 PCR or paired ELISA NS1 61.6 (55.2–67.8) 100 (93.8–100)
Osorio et al. [96] 2010 Colombia 2–7 (median: 4) Viral culture, PCR or
paired ELISA
NS1 57.7 (47.6–67.3) 95.3 (84.2–99.4)
Blacksell et al. [25] 2011 Sri Lanka Median 5; IQR 2–7 AFRIMS ELISA paired
samples
NS1 58.6 (48.2–68.4) 98.8 (95.6–99.9)
Tricou et al. [95] 2010 SD Bioline
Dengue Duo
Vietnam 1–6 PCR or paired ELISA NS1 62.4 (56.1–68.5) 100 (93.8–100)
Wang and Sekaran [97] 2010 Malaysia 1–15 Virus isolation, PCR,
paired ELISA
NS1 65.4 (58.5–72.3) 98.8 (96.2–100)
Osorio et al. [96] 2010 Colombia 2–7 (median: 4) Viral culture, PCR or
paired ELISA
NS1 51 (44.1–57.7) 96.7 (90.8–99.3)
Blacksell et al. [25] 2011 Sri Lanka Median 5; IQR 2–7 Paired ELISA NS1 48.5 (38.5–58.7) 99.4 (96.6–100)
Fry et al. [98] 2011 Panbio Early
Rapid NS1
Vietnam 1–5 (84.5%<3) PCR or paired ELISA NS1 69.2 (62.8–75.6) 96% (92.2–99.8)
Fry et al. [98] 2011 Malaysia 1–15 (70%  5) PCR or paired ELISA NS1 68.9 (61.8–76.1) 96.7 (82.8–99.9)
Blacksell et al. [25] 2011 Sri Lanka Median 5; IQR 2–7 Paired ELISA NS1 58.6 (48.2–68.4) 92.5 (87.3–96.1)
Wang and Sekaran [97] 2010 SD Bioline
Dengue Duo
Malaysia 1–15 Virus isolation, PCR,
rising titre in a
paired sample using
MAC ELISA
IgM 53.5 100
Blacksell et al. [25] 2011 Sri Lanka Median 5; IQR 2–7 Paired ELISA IgM 79.2 (70.5–87.2) 89.4 (83.5–93.7)
Blacksell et al. [25] 2011 Panbio Dengue
Duo Cassette
Sri Lanka Median 5; IQR 2–7 Paired ELISA IgM 70.7 (60.7–79.4) 80.0 (73.0–85.9)
Blacksell et al. [25] 2011 Merlin IgM Sri Lanka Median 5; IQR 2–7 Paired ELISA IgM 72.7 (62.9–81.2) 73.8 (66.2–80.4)
Blacksell et al. [25] 2011 Biosynex IgM Sri Lanka Median 5; IQR 2–7 Paired ELISA IgM 79.8 (70.5–87.2) 46.3 (38.3–54.3)
Tricou et al. [95] 2010 SD Dengue
Duo Bioline
Vietnam 1–6 PCR or paired ELISA NS1/IgM 75.5 (69.6–80.8) 100 (93.8–100)
NS1/IgM/IgG 83.7 (78.4–88.1) 97.9 (88.7–99.9)
Wang and Sekaran [97] 2010 Malaysia 1–15 Virus isolation, PCR,
paired ELISA
NS1/IgM 88.7 (84.0–93.3) 98.8 (96.3–100)
Osorio et al. [96] 2010 Colombia 2–7 (median: 4) Viral culture, PCR or
paired ELISA
NS1/IgM 78.4 (72.4–83.7) 91.3 (83.6–96.2)
NS1/IgM/IgG 80.7 (75–85.7) 89.1 (81–94.7)
Blacksell et al. [25] 2011 Sri Lanka Median 5; IQR 2–7 Paired ELISA NS1/IgM 92.9 (83.9–97.1) 88.8 (82.8–93.2
Fry et al. [98] 2011 Panbio Early Rapid
NS1 and Duo assay
Malaysia 1–15 (70%  5) PCR or paired ELISA NS1/IgM 89.0 (85.2–92.8) Not reported
NS1/IgM/IgG 93 Not reported
Blacksell et al. [25] 2011 Sri Lanka Median 5; IQR 2–7 Paired ELISA NS1/IgM 89.9 (82.2–95.0) 75.0 (67.6–81.5)
aStudies were included if: (i) study undertaken in a dengue endemic country; (ii) test detecting either NS1 or IgM or both; (iii) reference method including at least PCR or ELISA on
paired samples when evaluating NS1 and at least ELISA on paired samples when evaluating IgM; (iv) sample timing described; (v) study published from 2009 onwards.
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infection. The Rose Bengal test (RBT) is a rapid slide-
agglutination assay that uses a stained B. abortus suspension
to detect anti-Brucella antibodies. It has long been used as a
screening test in low-resource settings, but confusion about its
diagnostic accuracy led the WHO to recommend that positive
RBT results be conﬁrmed by another method. Concerns have
focused on perceived low sensitivity for chronic infection,
cross-reactivity with other pathogens and the prozone effect.
However, the RBT was recently assessed in a large study using
stored samples from culture-conﬁrmed cases (n = 208) and
controls with other illnesses (n = 1159) [54]. RBT results
were highly concordant with other serological methods,
except when positive titres were lower than 1:8, for which
conﬁrmation using another test appears necessary.
An RDT has recently been developed that could allow testing
at the point of care. The Lateral Flow immunochromatography
assayTM (LFiC; KIT) detects IgM and IgG to the polysaccharide
section of the Brucella S. lipopolysaccharide (S-LPS; O) antigen.
The test is simple, uses ﬁngerprick blood, does not require
refrigeration, and has shown sensitivity of 96–100% and
speciﬁcity reaching 99% when used for disease conﬁrmation,
compared with positive blood cultures [55,56], and high
concordance with standard serological methods [54,57]. Fur-
ther studies are needed to deﬁne LFiC performance in different
human epidemiological and clinical settings (e.g. relapse). The
LFiC is now produced by LifeAssay Diagnostics Ltd.
Human African trypanosomiasis
For decades, the card agglutination test for trypanosomiasis
(CATT) has been used for screening and diagnosis of T.
b. gambienseHAT. Although not an RDT sensu stricto (it requires
electricity and other equipment), it can be performed in remote
settings. Its diagnostic accuracy (sensitivity, 87–98% on undiluted
whole blood; speciﬁcity, 95%) has been evaluated in the context
of mass screening of predominantly asymptomatic individuals
[58], but never in clinically suspect patients (e.g. with persistent
fever or neurological disorders). A new and more practical
format (CATT-D10), with similar performance, has been devel-
oped to screen a smaller number of patients in peripheral health
facilities [59]. Two lateral ﬂow immunochromatographic RDTs
for the serodiagnosis of T. b. gambiense HAT have reached
advanced stages of development: (i) the ‘Immunochromato-
TABLE 3. Selected studies evaluating RDTs for enteric fevera
Author Year Assay Country
Sample timing
(days of illness)
True positive
deﬁnition
True negative
deﬁnition
Sensitivity%
(95% CI)
Speciﬁcity%
(95% CI)
Keddy
et al. [99]
2011 IDL TUBEX
TF (IgM)
South Africa
Tanzania
Not reporteda Automated blood
culture (Bac-T Alert)
Febrile patients with
negative blood cultures
73 (60.3–83.4) 69 (49.2–84.7)
Ley
et al. [100]
2011 Tanzania Not reporteda Automated blood
culture (BACTEC)
All non-typhi Bacteraemia 79 (52–81) 89 (81–94)
Naheed
et al. [101]
2008 Bangladesh Median 3
(range 1–30)
Manual blood culture Blood culture neg and
other bacteraemia
60 64
Kawano
et al. [102]
2007 Philippines Not reporteda Manual blood
culture and BACTEC
Febrile patients with
negative blood cultures
94.7 (86–98) 80.4 (71–87)
Dutta
et al. [36]
2006 India Median 4
(range 3–60)
Automated blood
culture (BACTEC)
Paratyphoid and
malaria cases
56 (47–66) 88 (82–94)
Olsen
et al. [103]
2004 Vietnam Median 11
(range 4–55)
Manual blood
culture and BACTEC
Other laboratory-conﬁrmed
diagnoses
78 (65–88) 94 (71–100)
House
et al. [104]
2001 Vietnam Median 12
(range 7–17)
Blood culture
(not speciﬁed)
Febrile patients with
negative blood cultures
87 (66–87) 76 (63–89)
Keddy
et al. [99]
2011 Typhidot (IgM) South Africa
Tanzania
Not reporteda Automated blood
culture (Bac-T Alert)
Febrile patients with
negative blood cultures
75.0 (61.1–86.0) 60.7 (40.6–78.5)
Kawano
et al. [102]
2007 Philippines Not reporteda Manual blood
culture and BACTEC
Febrile patients with
negative blood cultures
55 (43–66) 65 (55–74)
Dutta
et al. [36]
2006 India Median 4
(range 3–60)
Automated blood
culture (BACTEC)
Paratyphoid and malaria
cases
47 (37–58) 83 (71–94)
Olsen
et al. [103]
2004 Vietnam Median 11
(range 4–55)
Manual blood
culture and BACTEC
Other laboratory-conﬁrmed
diagnoses
79 (66–88) 89 (66–98)
Keddy
et al. [99]
2011 Typhidot (IgG) South Africa
Tanzania
Not reporteda Automated blood
culture (Bac-T Alert)
Febrile patients with
negative blood cultures
69.2 (54.9–81.3) 70.4 (49.8–86.2)
Kawano
et al. [102]
2007 Philippines Not reporteda Manual blood
culture and BACTEC
Febrile patients with
negative blood cultures
73 (62–83) 46 (36–56)
Naheed
et al. [101]
2008 Typhidot
Rapid IgM
IgG Combo
(IgM/IgG)
Bangladesh Median 3
(range 1–30)
Manual blood culture Blood culture neg and
other bacteraemia
67 (51–81) 54 (33–74)
Hatta
et al. [37]
2002 RTI LPS IgM
ICT (IgM)
Indonesia Median
(25–75IQR)
8 (5–11)
15 (12–18)
29 (25–31)
Manual blood culture Febrile hospitalized
patients with a ﬁnal
diagnosis other than
typhoid fever.
77.0 (61–89)
82.1 (66–92)
97.4 (87–100)
100 (98.5–100)
Kawano
et al. [102]
2007 SD Bioline
Typhoid
Rapid Test
(IgM/IgG)
Philippines Not reporteda Manual blood
culture and BACTEC
Febrile patients with
negative blood cultures
IgM: 69 (55–80)
IgG: 71 (59–81)
IgM: 79 (70–87)
IgG: 76 (70–83)
aStudies were included if (i) blood or bone marrow cultures were used as the reference standard, (ii) enteric fever clinical suspects were used for speciﬁcity calculations, (iii) 95%
conﬁdence intervals around performance estimates were given or calculable from presented data, and (iv) time elapsed since the onset of fever was indicated, because host
antibody responses and test sensitivity are time-dependent [37]. The results from Keddy et al. and Ley et al. [99,100] are reported despite the lack of timing data because they are
the only published high-quality studies in African populations. Results from Kawano et al. [102] are reported despite the lack of timing data because it is the only study evaluating
the RDT from SD Bioline.
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graphic HAT-RDT’, manufactured by Standard Diagnostics, in
collaboration with the Foundation for Innovative New Diagnos-
tics (FIND) and (ii) the ‘Gambiense-Sero-K-set’ developed by
Coris BioConcept (Gembloux, Belgium) in collaboration with
the Institute of Tropical Medicine, Antwerp. Results of phase 2
evaluations should be published soon for both RDTs, while phase
3 studies among clinically suspect patients are ongoing.
For T. b. rhodesiense HAT, there is no RDT in development.
Diagnosis is, however, straightforward with classic micros-
copy, because parasite load is usually high in the blood during
clinical illness.
Visceral leishmaniasis
The ﬁrst RDT detecting antibodies against rK39, a recombinant
antigen from Leishmania infantum, was evaluated in India in the
late 1990s [60]. A meta-analysis of 13 rK39 RDT evaluation
studies revealed an overall sensitivity of 93.7% and a speciﬁcity of
95.3%, with a trend towards decreased sensitivity in East Africa
[61]. This trend was conﬁrmed in recent studies, particularly
among HIV co-infected patients [62–64]. Only two rK39 RDTs
have been sufﬁciently validated for use in clinical practice, the
Kalazar DetectTM from Inbios, Seattle, WA, USA, and the IT-
LEISHTM from BioRad, Marnes-la-Coquette, France (formerly
from DiaMed AG, Switzerland). Both can conﬁrm VL, provided
that they are applied on strictly-deﬁned clinically suspect
patients (e.g.  2 weeks fever and splenomegaly), but a negative
rK39 RDT test result conﬁdently rules out VL in SouthAsia only,
highlighting the need for the development of a more sensitive
RDT for East Africa. Newly developed RDTs based on detection
of antibodies against rK28, a synthetic polyprotein, showed
promising sensitivity estimates (95.9–98.1%) in a limited number
of VL patients in Sudan and Bangladesh [65].
As antibodies remain detectable for years after treatment
[66], serological-based assays are useless to diagnose VL
relapses. For this purpose, efforts are currently being made to
transform an existing antigen detection test in urine (KAtexTM,
Kalon Biological Ltd, Guildford, UK) into a more practical
lateral ﬂow test.
Other febrile diseases
Rickettsial diseases are a large group of infections with
worldwide (e.g. murine typhus) or limited (e.g. scrub typhus)
distribution [67]. Diagnostic conﬁrmation can sometimes be
made clinically in the presence of a typical eschar (e.g. scrub
typhus), but most often relies on the detection of speciﬁc
antibodies, generally on paired samples. Serological RDTs have
been developed and validated for scrub typhus only, with very
variable sensitivity estimates (39–97%) [68–72]. Rapid diag-
nostic tests are in development for melioidosis, an infection
due to Burkholderia pseudomallei that is a frequent cause of
febrile illness and sepsis in southeastern Asia and northem
Australia. Numerous species of Borrelia spp may cause
relapsing fever, an underestimated cause of fever in some
tropical areas [9]. Despite the low sensitivity of classic
microscopy compared with molecular techniques [73], no
RDT has been developed to improve diagnosis in remote
settings.
Discussion
In many peripheral health facilities in the tropics, RDT-based
diagnosis of malaria is nowadays straightforward. Unfortu-
nately, once malaria is excluded, there are few accessible
diagnostic tools to guide the management of myriad severe
febrile illnesses [6]. This review summarizes the current state
of RDT development for several key infections and highlights
many remaining gaps.
Most RDTs for non-malarial tropical infections currently
rely on the detection of speciﬁc antibodies against a single
infectious agent. Antibodies usually take several days after
the appearance of fever to be detectable in peripheral
blood, which limits the sensitivity of serological RDTs in
acute fever [42,52,68]. Their speciﬁcity can also be altered
by cross-reactivity with other infectious agents, background
seroprevalence in the healthy exposed population and long-
term persistence of antibodies after infection [52,74]. The
latter may also prevent the use of serological RDTs to
monitor treatment response and/or to diagnose relapse
[75]. Considering the above limitations, there is an urgent
need to foster the development of sufﬁciently sensitive
antigen-based RDTs, as successfully accomplished for
malaria and dengue.
In many studies, evaluation of RDT accuracy is impaired by an
imperfect reference standard (e.g. blood culture for typhoid
fever, microscopic agglutination tests (MAT) for leptospirosis or
bone marrow aspiration for VL), leading to over-estimation of
RDT sensitivity and under-estimation of speciﬁcity. Optimizing
the choice of reference standard (e.g. using a composite
reference standard) or adjusting for the absence of reference
standard (e.g. applying latent class analysis) should be strongly
encouraged in all diagnostic studies evaluating the ‘true’ RDT
performance [76,77].
In addition to being highly accurate, RDTs need to be
affordable, user friendly, rapid and robust, equipment-free and
delivered to end-users, as summarized in the ASSURED
criteria [78]. Even if the ASSURED criteria are met, many
potential obstacles to widespread correct use of RDTs and
other point-of-curve tests remain, as recently reviewed
[78,79]. A striking feature is the lack of current production
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of many validated RDTs, possibly reﬂecting the fragile com-
mitment of manufacturers to maintaining the availability of
such tests, and the lack of regulatory and ﬁnancial conditions
that could facilitate or incentivise such commitments. The
advantages and pitfalls of RDTs in low resource settings are
summarized in the Box.
Box: Advantages and pitfalls of rdts in low-resource settings
Advantages of RDTs over conventional laboratory tests:
 Access to appropriate diagnosis-based management, i.e.
 Comparatively low skill required for use
 Minimal infrastructure requirements
 Low cost
 Rapid results in a clinically relevant time-frame
 Potentially increased standardization of care
Pitfalls and limitations of immunoassay-based RDTs:
Technical
 RDTs based on detection of host antibodies generally have low
sensitivity in the ﬁrst several days of disease – when treatment
might be most desirable. Moreover, the accuracy of such tests is
affected by host factors and prior infections.
 Despite having a broad range of operating and storage temper-
atures, antibodies used for RDT assembly may degrade in
extreme environments.
 Inherent limits in sensitivity when conventional colorimetric
detection is used. Inter-reader variability can be signiﬁcant,
especially for faint test lines.
 May be susceptible to the prozone phenomenon (i.e. falsely
negative or borderline results due to an excess of either the
antigen or the antibody of interest).
 Speciﬁcity may be severely decreased (i.e. false positives) in the
presence of concomitant conditions that cause polyclonal hyper-
gammaglobulinaemia.
Operational
 Training and quality assurance are essential: even the simplest RDTs
can be improperly used or misinterpreted, and inaccurate results
can harm patients and undermine their conﬁdence in local medical
services.
 Feasibility at the point-of-care: unlike conventional laboratory
services, health workers using RDTs might assume responsibility
for specimen collection and testing, as well as for quality control
and documentation. This will become an organizational challenge
as RDTs for an ever increasing list of diseases become available.
 User-interpretation of the signal, documentation and archiving of
results: these may be addressed by battery-operated automated
RDT readers, which digitally photograph RDT test strips,
uniformly interpret the results, and archive standardized photos
for subsequent quality assurance.
 One test = one disease: while microscopy and bacterial culture have
the ability to detect multiple pathogens at once, including
unsuspected ones, most existing RDTs only detect a single
pathogen. This limits the usefulness of current RDTs in the
management of some important clinical syndromes such as sepsis.
Current approaches to fever in low-resource settings are
most often fragmented or rely on non-speciﬁc clinical data and
empirical therapy. There is abundant evidence that this
approach is harmful and that integrated diagnostic pathways
for febrile illness are urgently needed [8]. In addition to the
development of locally validated RDTs, research priorities are
(i) ﬁlling the void of epidemiological knowledge in much of the
tropics (to assess pre-test probability) and (ii) developing
validated pathways combining key epidemiological and clinical
features with the use of RDTs, either alone or in tailored
panels, to better manage severe and treatable infections
requiring speciﬁc therapy.
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